Mumbai, Aug. 28 -- In a major enforcement action, the Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale (C&F) licences of M/s. Cipla Pharma & Life Sciences Ltd., Wadki, Pune, with effect from August 27, 2026.
The action has been taken in connection with Reactin Plus Tablets, a Schedule H prescription drug, the FDA said in a press note issued today.
According to FDA, during an inspection in June 2026 at the company's main warehouse at Wadki, district Pune, it was found that the packaging of Reactin Plus Tablets carried an unauthorised claim "Analgesic & Antipyretic".
Such advertisement of a prescription drug is in violation of the Drugs and Cosmetics Act, 1940 and Rules, 1945 and the drug was considered Misbranded...